Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Charles B Nguyen Melissa A Reimers Chamila Perera Wassim Abida Jonathan Chou Felix Y Feng Emmanuel S Antonarakis Rana R McKay Russell K Pachynski Jingsong Zhang Zachery R Reichert Phillip L Palmbos Megan E V Caram Ulka N Vaishampayan Elisabeth I Heath Alexander C Hopkins Marcin P Cieslik Yi-Mi Wu Dan R Robinson Veerabhadran Baladandayuthapani Arul M Chinnaiyan Ajjai Shivaram Alva

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

There was minimal activity with ICI therapy in patients with CDK12-altered mCRPC.

Keyphrases